TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES
ADVISORY COMMITTEE
January 18, 2001
Slides
Charge for Topic 1
Questions for Topic 1
Suitability of Blood & Plasma
Donors Who Traveled or Lived in BSE Countries: Further Consideration, David M
Asher, MD, CBER
Canadian Assessments & Policies
Concerning Deferral of Blood Donors Who Resided or Traveled in BSE/vCJD
Countries, Antonio Giulivi, MD, FRCPC, Canada
Consumption of Beef from the United
Kingdom by Service Members in Europe, 1980-1996, COL G. Michael Fitzpatrick, MD,
ASBPO & COL Scott R Severin, DVM, DODVSA, Office of the Army Surgeon General
Estimates of US Blood Donors Who
Traveled/Resided in Countries Exposed to BSE During 1980-1996, Alan E Williams,
PhD, American Red Cross etc.
Blood Data, Paul R McCurdy, MD
Aggregate Travel in the UK and
France, David Gaylor
Charge for Topic 2
Questions for Topic 2
Suitability Determination for
Donors of Human Cells, Tissues, & Cellular & Tissue-Based products: CJD
and vCJD, Ruth R Solomon, MD, CBER
Infectivity of Tissues & Fluids
of Humans with Transmissible Spongiform Encephalopathies, Clarence J Gibbs, Jr
PhD, NIH
Clinical & Experimental
Transmission of Creutzfeldt-Jakob Disease by Corneal Transplantation, R Nick
Hogan, MD, PhD, Univ. of Texas Southwestern Medical School
Cornea CJD Risk Assessment,
Sensitivity Analysis of the Risk Model, Rolf E Taffs, PhD, CBER
Donor Screening for TSE: Safety
& Supply of Corneal Transplants, David B Glasser, MD, Eye Bank Association
of America
The Risk of nvCJD in Recipients of
Hematopoietic Cell Transplants & the Impact of Deferring Donors from the UK,
Dennis L Confer, MD, National Marrow Donor Program
AATB Donor Screening Standards
& History Questionnaire, Duke Kasprisin, MD